This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Johnson & Johnson
Drug Names(s): ACH3102, ACH-0143102, ACH-3102
Description: ACH-3102 is a second generation NS5A inhibitor that in preclinical studies has demonstrated potent pan-genotypic activity against HCV genotypes 1 - 6. Preclinically, the drug has potency in the pico-molar range against HCV RNA replication, including potent activity against genotype 1a and enhanced activity against recognized genotype 1 resistant variants. Achillion's first generation NS5A inhibitor is ACH-2928.
The NS5A protein is a clinically validated target that serves multiple functions at various stages of the HCV life cycle including involvement in virion production, interaction with host proteins and association with interferon-resistance. In preclinical studies, Achillion's NS5A inhibitors, including ACH-3102, demonstrate additive to synergistic activity when combined with NS3 protease inhibitors, NS5B polymerase inhibitors, interferon and ribavirin.
Achillion and Janssen
In May 2015, Achillion entered into a worldwide license and collaboration arrangement with Janssen to develop and commercialize one or more of Achillion's lead hepatitis C virus (HCV) assets which include ACH-3102, ACH-3422, and sovaprevir.
Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets.
Additionally, in an equity transaction separate to...See full deal structure in Biomedtracker
Partners: Achillion Pharmaceuticals, Inc.
Additional information available to subscribers only: